FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295282> ?p ?o ?g. }

• W4286295282 endingPage "4517" @default.
• W4286295282 startingPage "4517" @default.
• W4286295282 abstract "4517 Background: Nearly half of the patients (pts) diagnosed with non-metastatic muscle invasive bladder cancer are unfit for cisplatin therapy and no alternative options of neoadjuvant treatment exist. Avelumab (A), a monoclonal antibody directed against PD-L1, showed efficacy in advanced urothelial cancer. We report preliminary data assessing preoperative avelumab associated with paclitaxel and gemcitabine or avelumab alone in the cisplatin ineligible cohort. The results of the cisplatin eligible cohort were reported at ESMO 2021. Methods: AURA is a prospective, multicenter, randomized, phase II trial for pts with cT2-4aN0-2M0 bladder carcinoma. Pts were enrolled in two separated cohorts based on eligibility for cisplatin chemotherapy. Cisplatin ineligible pts received 4 cycles of paclitaxel-gemcitabine (PG) plus A every 2 weeks or 4 cycles of A every 2 weeks (1:1). Primary endpoint was pCR rate (ypT0/isN0) with the objective, in each arm, to show pCR rate > 5% (90% power reached in case of pCR rate > 25%). Two-step design was used with planned interim analysis after 12 evaluable pts per arm. Secondary endpoints were pathologic downstaging rate ( < ypT2N0) and safety. Results: A total of 56 cisplatin-ineligible pts were evaluable. For PG + A arm (n = 28): median age was 72 years (41-80), 93% male. For A alone arm (n = 28): median age was 75 years (49-89), 93% male. One patient did not undergo surgery due to progression in the A arm but was included in intention to treat analysis. Five pts did not receive the 4 cycles of treatment; reasons included toxicity (n = 3) for PG + A arm and patient/physician decision (n = 2) for A arm. pCR was achieved in 5 pts (18%; 95%CI 6%-37%) treated with PG + A and 10 pts (36%; 95%CI 19%-56%) treated with A. Downstaging to < ypT2N0 was achieved in 6 pts (21%; 95%CI 8%-41%) and 11 pts (39%; 95%CI 22%-59%), respectively. Median time from treatment initiation to surgery was 82 days (55-144) for PG + A arm and 67 days (38-89) for A arm. Most common irAEs of any grade were asthenia (15%), skin toxicity and myalgia/arthralgia (each 5%). There were 2 pts in the PG + A arm with grade 3 irAEs (hepatitis and pneumonitis) that caused A discontinuation for 1 patient. No treatment-related deaths were reported. Conclusions: Neoadjuvant single agent avelumab resulted in high pCR and was safely administered without compromising surgical resection. Our results suggest that the addition of taxane-gemcitabine regimen to avelumab may reduce avelumab efficacy with low pCR rate. Survival analysis and correlative studies are underway. Clinical trial information: NCT03674424." @default.
• W4286295282 created "2022-07-21" @default.
• W4286295282 creator A5001474630 @default.
• W4286295282 creator A5010064853 @default.
• W4286295282 creator A5013221857 @default.
• W4286295282 creator A5014689698 @default.
• W4286295282 creator A5015535265 @default.
• W4286295282 creator A5030523847 @default.
• W4286295282 creator A5030902321 @default.
• W4286295282 creator A5043793171 @default.
• W4286295282 creator A5057557133 @default.
• W4286295282 creator A5057720244 @default.
• W4286295282 creator A5057841250 @default.
• W4286295282 creator A5057962494 @default.
• W4286295282 creator A5066545453 @default.
• W4286295282 creator A5069816168 @default.
• W4286295282 creator A5070807102 @default.
• W4286295282 creator A5072115484 @default.
• W4286295282 creator A5073295040 @default.
• W4286295282 creator A5076200732 @default.
• W4286295282 creator A5078203700 @default.
• W4286295282 creator A5088336773 @default.
• W4286295282 date "2022-06-01" @default.
• W4286295282 modified "2023-10-18" @default.
• W4286295282 title "Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial." @default.
• W4286295282 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.4517" @default.
• W4286295282 hasPublicationYear "2022" @default.
• W4286295282 type Work @default.
• W4286295282 citedByCount "8" @default.
• W4286295282 countsByYear W42862952822022 @default.
• W4286295282 countsByYear W42862952822023 @default.
• W4286295282 crossrefType "journal-article" @default.
• W4286295282 hasAuthorship W4286295282A5001474630 @default.
• W4286295282 hasAuthorship W4286295282A5010064853 @default.
• W4286295282 hasAuthorship W4286295282A5013221857 @default.
• W4286295282 hasAuthorship W4286295282A5014689698 @default.
• W4286295282 hasAuthorship W4286295282A5015535265 @default.
• W4286295282 hasAuthorship W4286295282A5030523847 @default.
• W4286295282 hasAuthorship W4286295282A5030902321 @default.
• W4286295282 hasAuthorship W4286295282A5043793171 @default.
• W4286295282 hasAuthorship W4286295282A5057557133 @default.
• W4286295282 hasAuthorship W4286295282A5057720244 @default.
• W4286295282 hasAuthorship W4286295282A5057841250 @default.
• W4286295282 hasAuthorship W4286295282A5057962494 @default.
• W4286295282 hasAuthorship W4286295282A5066545453 @default.
• W4286295282 hasAuthorship W4286295282A5069816168 @default.
• W4286295282 hasAuthorship W4286295282A5070807102 @default.
• W4286295282 hasAuthorship W4286295282A5072115484 @default.
• W4286295282 hasAuthorship W4286295282A5073295040 @default.
• W4286295282 hasAuthorship W4286295282A5076200732 @default.
• W4286295282 hasAuthorship W4286295282A5078203700 @default.
• W4286295282 hasAuthorship W4286295282A5088336773 @default.
• W4286295282 hasConcept C121608353 @default.
• W4286295282 hasConcept C126322002 @default.
• W4286295282 hasConcept C126894567 @default.
• W4286295282 hasConcept C141071460 @default.
• W4286295282 hasConcept C143998085 @default.
• W4286295282 hasConcept C203092338 @default.
• W4286295282 hasConcept C2776694085 @default.
• W4286295282 hasConcept C2777381376 @default.
• W4286295282 hasConcept C2777701055 @default.
• W4286295282 hasConcept C2778239845 @default.
• W4286295282 hasConcept C2780057760 @default.
• W4286295282 hasConcept C2780258809 @default.
• W4286295282 hasConcept C2780352672 @default.
• W4286295282 hasConcept C2781413609 @default.
• W4286295282 hasConcept C535046627 @default.
• W4286295282 hasConcept C61943457 @default.
• W4286295282 hasConcept C71924100 @default.
• W4286295282 hasConceptScore W4286295282C121608353 @default.
• W4286295282 hasConceptScore W4286295282C126322002 @default.
• W4286295282 hasConceptScore W4286295282C126894567 @default.
• W4286295282 hasConceptScore W4286295282C141071460 @default.
• W4286295282 hasConceptScore W4286295282C143998085 @default.
• W4286295282 hasConceptScore W4286295282C203092338 @default.
• W4286295282 hasConceptScore W4286295282C2776694085 @default.
• W4286295282 hasConceptScore W4286295282C2777381376 @default.
• W4286295282 hasConceptScore W4286295282C2777701055 @default.
• W4286295282 hasConceptScore W4286295282C2778239845 @default.
• W4286295282 hasConceptScore W4286295282C2780057760 @default.
• W4286295282 hasConceptScore W4286295282C2780258809 @default.
• W4286295282 hasConceptScore W4286295282C2780352672 @default.
• W4286295282 hasConceptScore W4286295282C2781413609 @default.
• W4286295282 hasConceptScore W4286295282C535046627 @default.
• W4286295282 hasConceptScore W4286295282C61943457 @default.
• W4286295282 hasConceptScore W4286295282C71924100 @default.
• W4286295282 hasIssue "16_suppl" @default.
• W4286295282 hasLocation W42862952821 @default.
• W4286295282 hasOpenAccess W4286295282 @default.
• W4286295282 hasPrimaryLocation W42862952821 @default.
• W4286295282 hasRelatedWork W1967786039 @default.
• W4286295282 hasRelatedWork W2008828217 @default.
• W4286295282 hasRelatedWork W2100029565 @default.
• W4286295282 hasRelatedWork W2349270370 @default.
• W4286295282 hasRelatedWork W2350704511 @default.
• W4286295282 hasRelatedWork W2374795505 @default.
• W4286295282 hasRelatedWork W2381460883 @default.
• W4286295282 hasRelatedWork W2390617104 @default.

• next